20 April 2015 in Plant Physiology
Polycomb Group (PcG) proteins play important roles in regulating developmental phase transitions in plants; however, little is known about the role the PcG machinery in regulating the transition from juvenile to adult phase. Here, we show that Arabidopsis BMI1 (AtBMI1) PRC1 components participate in the repression of miR156. Loss of AtBMI1 function leads to upregulation of pri-MIR156A/C at the time the levels of miR156 should decline, resulting in an extended juvenile phase and delayed flowering. Conversely, the PRC1 component EMBRYONIC FLOWER (EMF1) participates in the regulation of SPL and MIR172 genes. Accordingly, plants impaired in EMF1 function displayed misexpression of these genes early in development, which contributes to a CONSTANS (CO)-independent upregulation of FLOWERING LOCUS T (FT) leading to the earliest flowering phenotype described in Arabidopsis. Our findings show how the different regulatory roles of two functional PRC1 variants coordinate the acquisition of flowering competence and help to reach the threshold of FT necessary to flower. Furthermore, we show how two central regulatory mechanisms, such as PcG and miRNA, assemble to achieve a developmental outcome.
27 November 2023 in Nature Aging
29 September 2021 in Science Translational Medicine
Altered CPEBs and mRNA polyadenylation lead to thiamine deficiency in the brains of patients and mice with Huntington’s disease.
16 December 2024 in Research Square
AAAlejandro Alonso-Calleja
+15
Aging is the major risk factor for most human diseases and represents a major socio-economical challenge for modern societies. Despite its importance, the process of aging remains poorly understood. Epigenetic dysregulation has been proposed as a key driver of the aging process. Alterations in transcriptional networks and chromatin structure might be central to age-related functional decline. A prevalent feature described during aging is the overall reduction in heterochromatin, specifically marked by the loss of the repressive histone modification, histone 3 lysine 9 trimethylation (H3K9me3). However, the role of H3K9me3 in aging, especially in mammals, remains unclear. Here we show using a novel mouse strain, “TKOc”, carrying a triple knockout of three methyltransferases responsible for H3K9me3 deposition, that the inducible loss of H3K9me3 in adulthood results in premature aging. TKOc mice exhibit reduced lifespan, lower body weight, increased frailty index, multi-organ degeneration, transcriptional changes with significant upregulation of transposable elements, and accelerated epigenetic age. Our data strongly supports the concept that the loss of epigenetic information might directly drives the aging process. These findings reveal the importance of epigenetic regulation in aging and suggest that interventions targeting epigenetic modifications could potentially slow down or reverse age-related decline. Understanding the molecular mechanisms underlying the process of aging will be crucial for developing novel therapeutic strategies that can delay the onset of age-associated diseases and preserve human health at old age specially in rapidly aging societies.
7 October 2025 in NAR Molecular Medicine
AMAinhoa Martinez-Pizarro
+3
Microexons are enriched in genes linked to autism spectrum disorders (ASDs). We have previously demonstrated decreased inclusion of a neuronal specific 24 bp microexon of the translational regulator CPEB4 in brains of idiopathic ASD cases and that this leads to CPEB4 aggregation and subsequent under-expression of multiple high confidence ASD-risk genes. Furthermore, decreased inclusion of the CPEB4 microexon is also a novel etiological mechanism in schizophrenia (SCZ). In this work, we designed a series of splice switching antisense oligonucleotides (SSOs) targeting the CPEB4 microexon genomic region. SSOs targeting intronic regions near the microexon resulted in a decrease in microexon inclusion in neuroblastoma cells, by blocking hnRNPC binding, mimicking the isoform imbalance observed in ASD. Interestingly, we identified SSOs targeting downstream 3′ splice site of exon 5 that favoured microexon inclusion in a dose-dependent manner and resulted in increased protein levels of AUTS2 and DIRK1A, two high-confidence ASD risk genes, targets of CPEB4, with reduced protein levels in ASD. These results deepen our understanding of the complex splicing regulation of microexons and open new applications of SSOs to treat diseases, such as ASD and SCZ, characterized by altered microexon inclusion.